Genesis Therapeutics announces AI discovery deal with Eli Lilly, $20M in upfront cash with potential total value of $670M.
Read more ->
Home
Company
Platform
Press
Careers
Contact Us
Company
Platform
Press
Careers
Contact Us
In the press
Genesis Therapeutics announces AI discovery deal with Eli Lilly, $20M in upfront cash with potential total value of $670M
Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using the Genesis Molecular AI Platform
Genesis Therapeutics Hires Will McCarthy as Chief Business Officer
Genesis Therapeutics Secures $52M Series A, Led by Rock Springs Capital
Genesis Therapeutics raises $52M A round for its AI-focused drug discovery mission
Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech
Roche's James Sabry partners Genentech with Stanford spinout Genesis Therapeutics
Genentech taps Stanford University spinout for AI drug discovery partnership
AI 50: America’s Most Promising Artificial Intelligence Companies
30 Under 30: Healthcare 2020
Five Questions with a16z’s Vijay Pande on AI and Making New Drugs
Genesis Therapeutics Raises $4.1M Seed, Led by Andreessen Horowitz
An Interview with Evan Feinberg